vs
Journey Medical Corp（DERM）与UNIVERSAL HEALTH REALTY INCOME TRUST（UHT）财务数据对比。点击上方公司名可切换其他公司
UNIVERSAL HEALTH REALTY INCOME TRUST的季度营收约是Journey Medical Corp的1.5倍（$24.5M vs $16.1M），UNIVERSAL HEALTH REALTY INCOME TRUST净利率更高（17.7% vs -7.8%，领先25.4%），Journey Medical Corp同比增速更快（27.3% vs -0.7%），过去两年Journey Medical Corp的营收复合增速更高（11.0% vs -1.3%）
Journey Medical Corp是一家处于商业化阶段的生物制药企业，专注于皮肤病治疗领域，研发、生产并销售处方及非处方皮肤用药，覆盖痤疮、特应性皮炎、皮肤真菌感染等适应症，主要服务美国市场的医疗机构与患者。
环球健康服务公司（UHS）是一家总部位于宾夕法尼亚州普鲁士国王市的美国医疗服务企业，位列财富500强，主营医院运营及各类医疗保健服务。该公司2024年公布的总营收达158亿美元。
DERM vs UHT — 直观对比
营收规模更大
UHT
是对方的1.5倍
$16.1M
营收增速更快
DERM
高出28.0%
-0.7%
净利率更高
UHT
高出25.4%
-7.8%
两年增速更快
DERM
近两年复合增速
-1.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $16.1M | $24.5M |
| 净利润 | $-1.2M | $4.3M |
| 毛利率 | — | — |
| 营业利润率 | -2.8% | 34.7% |
| 净利率 | -7.8% | 17.7% |
| 营收同比 | 27.3% | -0.7% |
| 净利润同比 | -182.0% | -7.2% |
| 每股收益（稀释后） | $-0.04 | $0.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DERMUHT
| Q4 25 | $16.1M | $24.5M | ||
| Q3 25 | $17.0M | $25.3M | ||
| Q2 25 | $15.0M | $24.9M | ||
| Q1 25 | $13.1M | $24.5M | ||
| Q4 24 | $12.6M | $24.6M | ||
| Q3 24 | $14.6M | $24.5M | ||
| Q2 24 | $14.9M | $24.7M | ||
| Q1 24 | $13.0M | $25.1M |
净利润DERMUHT
| Q4 25 | $-1.2M | $4.3M | ||
| Q3 25 | $-2.3M | $4.0M | ||
| Q2 25 | $-3.8M | $4.5M | ||
| Q1 25 | $-4.1M | $4.8M | ||
| Q4 24 | $1.5M | $4.7M | ||
| Q3 24 | $-2.4M | $4.0M | ||
| Q2 24 | $-3.4M | $5.3M | ||
| Q1 24 | $-10.4M | $5.3M |
毛利率DERMUHT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 82.3% | — | ||
| Q3 24 | 63.9% | — | ||
| Q2 24 | 56.0% | — | ||
| Q1 24 | 47.7% | — |
营业利润率DERMUHT
| Q4 25 | -2.8% | 34.7% | ||
| Q3 25 | -9.0% | 33.2% | ||
| Q2 25 | -19.2% | 35.6% | ||
| Q1 25 | -25.3% | 36.8% | ||
| Q4 24 | 17.7% | 37.6% | ||
| Q3 24 | -19.8% | 34.7% | ||
| Q2 24 | -19.7% | 38.7% | ||
| Q1 24 | -77.4% | 37.6% |
净利率DERMUHT
| Q4 25 | -7.8% | 17.7% | ||
| Q3 25 | -13.6% | 15.9% | ||
| Q2 25 | -25.3% | 18.1% | ||
| Q1 25 | -31.0% | 19.5% | ||
| Q4 24 | 12.1% | 18.9% | ||
| Q3 24 | -16.3% | 16.3% | ||
| Q2 24 | -22.6% | 21.3% | ||
| Q1 24 | -80.1% | 21.1% |
每股收益（稀释后）DERMUHT
| Q4 25 | $-0.04 | $0.32 | ||
| Q3 25 | $-0.09 | $0.29 | ||
| Q2 25 | $-0.16 | $0.32 | ||
| Q1 25 | $-0.18 | $0.34 | ||
| Q4 24 | $0.10 | $0.34 | ||
| Q3 24 | $-0.12 | $0.29 | ||
| Q2 24 | $-0.17 | $0.38 | ||
| Q1 24 | $-0.53 | $0.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $24.1M | $6.7M |
| 总债务越低越好 | $25.3M | $374.8M |
| 股东权益账面价值 | $31.9M | $152.4M |
| 总资产 | $94.6M | $564.9M |
| 负债/权益比越低杠杆越低 | 0.79× | 2.46× |
8季度趋势，按日历期对齐
现金及短期投资DERMUHT
| Q4 25 | $24.1M | $6.7M | ||
| Q3 25 | $24.9M | $6.9M | ||
| Q2 25 | $20.3M | $6.6M | ||
| Q1 25 | $21.1M | $7.0M | ||
| Q4 24 | $20.3M | $7.1M | ||
| Q3 24 | $22.5M | $6.4M | ||
| Q2 24 | $23.9M | $5.6M | ||
| Q1 24 | $24.1M | $7.7M |
总债务DERMUHT
| Q4 25 | $25.3M | $374.8M | ||
| Q3 25 | $25.2M | — | ||
| Q2 25 | $25.1M | — | ||
| Q1 25 | $25.0M | — | ||
| Q4 24 | $24.9M | $368.4M | ||
| Q3 24 | $19.8M | — | ||
| Q2 24 | $19.7M | — | ||
| Q1 24 | $14.7M | — |
股东权益DERMUHT
| Q4 25 | $31.9M | $152.4M | ||
| Q3 25 | $25.9M | $158.6M | ||
| Q2 25 | $19.2M | $165.2M | ||
| Q1 25 | $21.5M | $172.2M | ||
| Q4 24 | $20.1M | $179.5M | ||
| Q3 24 | $10.9M | $181.6M | ||
| Q2 24 | $11.3M | $190.7M | ||
| Q1 24 | $13.0M | $196.5M |
总资产DERMUHT
| Q4 25 | $94.6M | $564.9M | ||
| Q3 25 | $85.2M | $568.0M | ||
| Q2 25 | $81.2M | $573.0M | ||
| Q1 25 | $85.0M | $573.5M | ||
| Q4 24 | $80.2M | $580.9M | ||
| Q3 24 | $64.0M | $584.3M | ||
| Q2 24 | $65.2M | $586.6M | ||
| Q1 24 | $66.6M | $596.2M |
负债/权益比DERMUHT
| Q4 25 | 0.79× | 2.46× | ||
| Q3 25 | 0.97× | — | ||
| Q2 25 | 1.30× | — | ||
| Q1 25 | 1.16× | — | ||
| Q4 24 | 1.24× | 2.05× | ||
| Q3 24 | 1.81× | — | ||
| Q2 24 | 1.75× | — | ||
| Q1 24 | 1.13× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-6.3M | $49.1M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | 11.35× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流DERMUHT
| Q4 25 | $-6.3M | $49.1M | ||
| Q3 25 | $-2.4M | $10.2M | ||
| Q2 25 | $-942.0K | $13.7M | ||
| Q1 25 | $-2.8M | $11.6M | ||
| Q4 24 | $2.2M | $46.9M | ||
| Q3 24 | $-1.2M | $9.9M | ||
| Q2 24 | $-5.2M | $12.1M | ||
| Q1 24 | $-5.0M | $11.7M |
现金转化率DERMUHT
| Q4 25 | — | 11.35× | ||
| Q3 25 | — | 2.54× | ||
| Q2 25 | — | 3.05× | ||
| Q1 25 | — | 2.43× | ||
| Q4 24 | 1.46× | 10.06× | ||
| Q3 24 | — | 2.48× | ||
| Q2 24 | — | 2.30× | ||
| Q1 24 | — | 2.21× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
UHT
| Reportable Segment Aggregation Before Other Operating Segment | $23.1M | 94% |
| Equity Method Investment Nonconsolidated Investee Or Group Of Investees | $2.3M | 9% |
